Articles tagged with 'SPECIALIZED PRESS' | Bayer

Newsroom Bayer (SPECIALIZED PRESS)

2023
September
28,
2023
| 08:29 AM Europe/Amsterdam
Presentations at EURETINA capture 60-week data, a key secondary endpoint, and two-year data (96-week) from the pivotal PULSAR and PHOTON clinical trials that provide insights into durability of extended treatment intervals as well as efficacy and saf...
Read more
September
27,
2023
| 13:59 PM Europe/Amsterdam
Real-world evidence (RWE) research results on treatment utilization and pathways in women with menopausal symptoms via poster presentations on the CHAPTER natural menopause study, CHAPTER i-menopause study and REALISE study / These poster presentatio...
Read more
September
21,
2023
| 14:29 PM Europe/Amsterdam
Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and eff...
Read more
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...
Read more
August
28,
2023
| 07:59 AM Europe/Amsterdam
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year. / At one-year, exploratory clinical endpoints improved overall, with...
Read more
August
24,
2023
| 10:29 AM Europe/Amsterdam
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...
Read more
August
10,
2023
| 12:59 PM Europe/Amsterdam
Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomize...
Read more
June
29,
2023
| 08:29 AM Europe/Amsterdam
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...
Read more
June
27,
2023
| 08:29 AM Europe/Amsterdam
Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) featuring high relaxivity with the potential for a substantially lower gadolinium (Gd) dose / QUANTI clinical development program includes two Phase III studies in ad...
Read more
June
22,
2023
| 08:29 AM Europe/Amsterdam
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...
Read more
June
21,
2023
| 08:29 AM Europe/Amsterdam
Partnership will enhance clinical adoption of artificial intelligence (AI) in medical imaging  / AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity of radiology interventions...
Read more
June
15,
2023
| 08:59 AM Europe/Amsterdam
New post hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will validate a model predicting the risk of chronic kidney disease (CKD) progression in adults at all stages of CKD / Update on FINEGUST study, descri...
Read more
June
01,
2023
| 13:59 PM Europe/Amsterdam
Phase II/III study VALOR will assess efficacy, safety and pharmacokinetics of vericiguat in pediatric patients / VALOR is the pivotal study in pediatric heart failure with vericiguat
Read more
May
25,
2023
| 13:59 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 ...
Read more
May
17,
2023
| 13:59 PM Europe/Amsterdam
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase II...
Read more
May
16,
2023
| 08:29 AM Europe/Amsterdam
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in st...
Read more
May
10,
2023
| 09:59 AM Europe/Amsterdam
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macula...
Read more
May
09,
2023
| 08:59 AM Europe/Amsterdam
Poster presentation from the REALISE study, a real-world evidence analysis evaluating the status of treatment of vasomotor symptoms (VMS) and symptom burden in women taking adjuvant endocrine therapy (AET) after breast cancer, showing a need for new ...
Read more
May
02,
2023
| 09:00 AM Europe/Amsterdam
Poster presentation on the EMPOWER study, a qualitative analysis from interviews with menopausal women, shows the importance of vasomotor symptoms (VMS), as well as potential treatment side effects on the women’s treatment decisions / Poster presenta...
Read more
April
17,
2023
| 12:59 PM Europe/Amsterdam
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg / In total, 18 present...
Read more
April
11,
2023
| 12:59 PM Europe/Amsterdam
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 / New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs o...
Read more
March
24,
2023
| 14:59 PM Europe/Amsterdam
Late-stage development programs with significant potential to drive long-term growth / New R&D strategy and operating model sharpening innovation focus and strengthening early development pipeline in oncology, cardiovascular, neurology & rare disease...
Read more
March
23,
2023
| 13:59 PM Europe/Amsterdam
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...
Read more
March
20,
2023
| 07:59 AM Europe/Amsterdam
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...
Read more
March
06,
2023
| 09:59 AM Europe/Amsterdam
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chro...
Read more
March
01,
2023
| 11:59 AM Europe/Amsterdam
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...
Read more
March
01,
2023
| 07:59 AM Europe/Amsterdam
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...
Read more
February
27,
2023
| 07:59 AM Europe/Amsterdam
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 
Read more
February
22,
2023
| 08:29 AM Europe/Amsterdam
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI / Further research explores potential of AI and digital advances in medical imaging 
Read more
February
13,
2023
| 08:29 AM Europe/Amsterdam
Closing follows announcement of acquisition on January 18, 2023 / Acquisition bolsters Bayer’s position in digital medical imaging / Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneur...
Read more